Literature DB >> 19101094

Postoperative strontium-90 brachytherapy in the prevention of keloids: results and prognostic factors.

Gustavo A Viani1, Eduardo J Stefano, Sergio L Afonso, Ligia I De Fendi.   

Abstract

PURPOSE: The aim of this study was to evaluate the results of keloidectomy and strontium 90 brachytherapy in the prevention of keloid recurrence following excision and to identify outcome and the prognostic factors that predict keloid recurrence after irradiation. METHODS AND MATERIALS: Data of 612 patients with 892 keloids treated between 1992 and 2006 were evaluated retrospectively. Brachytherapy was performed using a Sr-90Y surface applicator. Total dose was 20 Gy in 10 fractions.
RESULTS: With a median follow-up of 61 months, the overall recurrence-free response rate for all keloids was 87.6%. Multivariate analysis revealed the following prognostic factors for recurrence: keloid size > 5 cm (p < 0.0001), burn scars as the keloid etiology (p < 0.0001), and previous treatment (p < 0.0001). Outcome was not found to be significantly related to the interval between surgery and radiotherapy, sex, or age. Pruritus and skin reddening were the most common symptoms of keloids, but all signs and symptoms abated with time after treatment. Cosmetic results from the keloid treatment were considered good or excellent in 70.6% of the patients.
CONCLUSION: Our study findings show that excision plus Sr-90 brachytherapy is effective in the eradication of keloids. Sr-90 radiotherapy (20 Gy in 10 fractions) achieved a similar local control rate, as have higher doses per fraction in other series. It also resulted in a good cosmetic rate and relief of symptoms. Our data further suggest that the initiation of postoperative irradiation within hours of surgical excision is not important to therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101094     DOI: 10.1016/j.ijrobp.2008.07.065

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Adjuvance in refractory keloids using electron beams with a spoiler: Recent results.

Authors:  Antoni Vila Capel; Jorge Vilar Palop; Agustí Pedro Olivé; Alberto Sánchez-Reyes Fernández
Journal:  Rep Pract Oncol Radiother       Date:  2014-08-28

Review 2.  Adjuvant Radiotherapy for Keloids.

Authors:  Wenfang Dong; Bin Qiu; Fei Fan
Journal:  Aesthetic Plast Surg       Date:  2021-08-20       Impact factor: 2.326

3.  Risk factors of recurrence after postoperative electron beam radiation therapy for keloid: Comparison of long-term local control rate.

Authors:  Hitoshi Maemoto; Shiro Iraha; Ken Arashiro; Kousei Ishigami; Fumikiyo Ganaha; Sadayuki Murayama
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-19

4.  Treatment of retroauricular keloids: Revision of cases treated at the ENT service of HC/UFPR.

Authors:  Bettina Carvalho; Annelyse Cristine Ballin; Renata Vecentin Becker; Talita Beithum Ribeiro; Juliana Benthien Cavichiolo; Carlos Roberto Ballin; Marcos Mocellin
Journal:  Int Arch Otorhinolaryngol       Date:  2012-04

Review 5.  Radiation Therapy in Keloids Treatment: History, Strategy, Effectiveness, and Complication.

Authors:  Jing Xu; Elan Yang; Nan-Ze Yu; Xiao Long
Journal:  Chin Med J (Engl)       Date:  2017-07-20       Impact factor: 2.628

Review 6.  Brachytherapy in the adjuvant management of keloid scars: literature review.

Authors:  Ioannis Goutos; Rei Ogawa
Journal:  Scars Burn Heal       Date:  2017-11-10

7.  Perioperative interstitial high-dose-rate brachytherapy for keloids scar.

Authors:  Victoria Vera Barragán; Ana Isabel Alonso García; José Fernández García; Marta De Juan Marín; Johanna Del Carmen Peña Vivas; Germán Juan Rijo
Journal:  J Contemp Brachytherapy       Date:  2022-02-18

8.  Image-guided high-dose-rate intracavitary brachytherapy technique for nasal keloid - a case report.

Authors:  Cheng Huang; Mingyuan He; Hongfu Zhao; Prof Guanghui Cheng
Journal:  J Contemp Brachytherapy       Date:  2018-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.